SAGE-718   Click here for help

GtoPdb Ligand ID: 12050

Synonyms: compound 5 [PMID: 35785990] [1] | SAGE718
Compound class: Synthetic organic
Comment: SAGE-718 is a positive allosteric modulator (PAM) of N-Methyl-D-aspartate (NMDA) receptors that was designed as a potential treatment for cognitive impairment [1]. Its pharmacokinetics support oral dosing.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 40.46
Molecular weight 456.32
XLogP 9.4
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES C[C@@H]([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC=C2[C@]1(C)CC[C@](C2)(C)O)CC[C@@](C(F)(F)F)(O)C
Isomeric SMILES C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]1[C@H]2CC=C2[C@@]1(CC[C@](C2)(C)O)C)C
InChI InChI=1S/C27H43F3O2/c1-17(10-13-26(5,32)27(28,29)30)20-8-9-21-19-7-6-18-16-23(2,31)14-15-24(18,3)22(19)11-12-25(20,21)4/h6,17,19-22,31-32H,7-16H2,1-5H3/t17-,19+,20-,21+,22+,23+,24+,25-,26+/m1/s1
No information available.
Summary of Clinical Use Click here for help
Sage Therapeutics have advanced SAGE-718 as a clinical lead, to evaluate its capacity to improve cognitive impairment that is associated with dementias, Huntington's disease and Parkinson's disease.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04602624 A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) Phase 2 Interventional Sage Therapeutics
NCT05107128 A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) Phase 2 Interventional Sage Therapeutics
NCT05318937 A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment Phase 2 Interventional Sage Therapeutics